[go: up one dir, main page]

MX2019009546A - Anticuerpos anti-factor d y uso de los mismos. - Google Patents

Anticuerpos anti-factor d y uso de los mismos.

Info

Publication number
MX2019009546A
MX2019009546A MX2019009546A MX2019009546A MX2019009546A MX 2019009546 A MX2019009546 A MX 2019009546A MX 2019009546 A MX2019009546 A MX 2019009546A MX 2019009546 A MX2019009546 A MX 2019009546A MX 2019009546 A MX2019009546 A MX 2019009546A
Authority
MX
Mexico
Prior art keywords
factor
antibodies
antibody
individual
relates
Prior art date
Application number
MX2019009546A
Other languages
English (en)
Inventor
Song Wenchao
Zhou Lin
Sato Sayaka
Miwa Takashi
Gullipalli Damodar
Golla Madhu
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2019009546A publication Critical patent/MX2019009546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a la inhibición selectiva de la trayectoria alternativa (AP) del sistema del complemento utilizando un anticuerpo anti-factor D; específicamente, la invención se refiere a métodos para tratar una enfermedad mediada por AP o un trastorno mediado por AP en un individuo al poner en contacto al individuo con un anticuerpo anti-factor D.
MX2019009546A 2017-02-10 2018-02-09 Anticuerpos anti-factor d y uso de los mismos. MX2019009546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762457477P 2017-02-10 2017-02-10
PCT/US2018/017537 WO2018148486A1 (en) 2017-02-10 2018-02-09 Anti-factor d antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2019009546A true MX2019009546A (es) 2019-12-16

Family

ID=63107085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009546A MX2019009546A (es) 2017-02-10 2018-02-09 Anticuerpos anti-factor d y uso de los mismos.

Country Status (13)

Country Link
US (2) US11434279B2 (es)
EP (1) EP3580241A4 (es)
JP (2) JP2020507581A (es)
KR (1) KR20190129859A (es)
CN (1) CN110461879B (es)
AU (1) AU2018217720A1 (es)
BR (1) BR112019016574A2 (es)
CA (1) CA3053155A1 (es)
EA (1) EA201991876A1 (es)
IL (1) IL268601B2 (es)
MX (1) MX2019009546A (es)
SG (1) SG11201907369TA (es)
WO (1) WO2018148486A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018217720A1 (en) * 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
EP3592386A4 (en) * 2017-03-06 2021-01-13 The Trustees Of The University Of Pennsylvania ANTI-C5 ANTIBODIES AND THEIR USES
JP7653909B2 (ja) 2018-09-06 2025-03-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト化抗ｃ５抗体とその利用
CN110240652B (zh) * 2019-06-05 2022-09-06 百奥泰生物制药股份有限公司 抗补体d因子抗体及其应用
WO2021202836A1 (en) * 2020-04-01 2021-10-07 The Trustees Of The University Of Pennsylvania Factor b inhibitors and uses thereof
AU2021270867A1 (en) 2020-05-12 2022-12-08 Alexion Pharmaceuticals, Inc. Use of complement factor D inhibitors alone or in combination with anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
CA3189666A1 (en) * 2020-08-18 2022-02-24 William Jason Cummings Monoclonal antibodies, compositions and methods for detecting complement factor d
CN114517184A (zh) * 2020-10-30 2022-05-20 未来智人再生医学研究院(广州)有限公司 一种表达adipsin的多能干细胞或其衍生物及应用
JP2024515066A (ja) * 2021-04-09 2024-04-04 武田薬品工業株式会社 補体因子ｄを標的とする抗体及びその使用
CN119306826B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗白介素-6抗体、检测白介素-6的试剂和试剂盒
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
CN119769642B (zh) * 2025-02-21 2025-08-26 广州达牧生物科技有限公司 一种猪饲料、饲料添加剂及其制备方法
CN120695186A (zh) * 2025-06-25 2025-09-26 辽宁省肿瘤医院 Cfd作为靶点在胃癌腹膜转移中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
AU762050B2 (en) * 1998-02-20 2003-06-19 Genentech, Inc. Inhibitors of complement activation
US7435804B2 (en) * 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
US7989595B2 (en) 2005-06-20 2011-08-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2500030B2 (en) 2005-11-04 2018-08-08 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
AU2013200987A1 (en) 2006-11-02 2013-03-14 Genentech, Inc. Humanized anti-Factor D antibodies
MY157948A (en) 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
AU2016202258A1 (en) 2007-05-23 2016-05-05 Genentech, Inc. Prevention and treatment of complement-associated eye conditions
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
AU2013213753A1 (en) * 2007-05-23 2013-08-29 Genentech, Inc. Prevention and treatment of complement-associated eye conditions
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2011140114A2 (en) 2010-05-03 2011-11-10 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
CN105153304B (zh) 2012-06-08 2018-09-11 厦门大学 抗hpv l1蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
MX2016014160A (es) * 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
AU2018217720A1 (en) * 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof

Also Published As

Publication number Publication date
CN110461879A (zh) 2019-11-15
EP3580241A4 (en) 2021-01-06
IL268601B2 (en) 2024-07-01
JP2023040069A (ja) 2023-03-22
EP3580241A1 (en) 2019-12-18
WO2018148486A8 (en) 2019-09-19
CA3053155A1 (en) 2018-08-16
BR112019016574A2 (pt) 2020-03-31
SG11201907369TA (en) 2019-09-27
IL268601A (en) 2019-09-26
WO2018148486A1 (en) 2018-08-16
CN110461879B (zh) 2024-03-29
AU2018217720A1 (en) 2019-09-05
RU2019128203A (ru) 2021-03-10
US20190359699A1 (en) 2019-11-28
EA201991876A1 (ru) 2020-03-13
JP2020507581A (ja) 2020-03-12
IL268601B1 (en) 2024-03-01
US11434279B2 (en) 2022-09-06
KR20190129859A (ko) 2019-11-20
US20230032737A1 (en) 2023-02-02
RU2019128203A3 (es) 2021-11-12

Similar Documents

Publication Publication Date Title
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
ZA201905866B (en) Anti-c5 antibodies and uses thereof
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
PH12019502283A1 (en) Anti-lag3 antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
MX2020000960A (es) Anticuerpos anti-tigit.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
EA201992546A1 (ru) Средства на основе антител к cd33
MX373581B (es) Anticuerpos humanos frente a la proteína de anclaje del coronavirus causante del síndrome respiratorio de oriente medio.
MY205689A (en) Antibody molecules to cd138 and uses thereof
NZ748777A (en) Binding molecules specific for fcγriia and uses thereof
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
NZ746609A (en) Ilt7 binding molecules and methods of using the same
MX2020006297A (es) Variantes de cd19.
WO2013006449A3 (en) Anti-properdin antibodies and uses thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка